No Prescription

Alpha Index H

No Prescription » Products » Alpha Index H

List of Drugs:

A  B  C  D  E  F  G  H  I  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Z  #

Products H:

Hansepran Lamprene

Heartcare Plus for Large dogs 23 to 45kg Heartgard Plus

Heartcare Plus for Medium dogs 12 to 22kg Heartgard Plus

Heartcare Plus for Small dogs Upto 11kg Heartgard Plus

Heart & Circulation Tonic

Helkoss Zantac

Hernovir Zovirax

HIPRESS Tenormin

HISONE Cortef

HOSTACYCLIN Achromycin V

Human Growth Agent

Hyalgan Injection Hyalgan

HYDERGINE Generic Co Dergocrine Mesylate

HYDRAZIDE Esidrix

Hydrea Droxia

Hydrea (Hydroxyurea)

Hydrocortisone Generic Hisone

Hytrin Generic Terazosin

Hytrin (Terazosin)

Hyzaar Forte Generic Losartan and Hydrochlorthiazide

Hyzaar Generic Losartan and Hydrochlorthiazide

Hyzaar (Losartan + Hydrochlorothiazide)

Previous  Next

No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.